Chronic traumatic encephalopathy is a neurogenerative disease linked to repeated trauma to the head. The encephalopathy symptoms can include behavioral problems, mood problems, and problems with thinking. The disease often gets worse over time and can result in dementia. Symptoms of chronic traumatic encephalopathy, which occur in four stages, generally appear eight to ten years after an individual experiences repetitive mild traumatic brain injury. First-stage symptoms are confusion, disorientation, dizziness, and headaches. Second-stage symptoms include memory loss, social instability, impulsive behavior, and poor judgment. The third and fourth stages include progressive dementia, movement disorders, hypomimia, speech impediments, sensory processing disorder, tremors, vertigo, deafness, depression, and suicidality. Most documented cases have occurred in athletes with mild repetitive head impacts over an extended time. Evidence indicates that repetitive concussive and sub-concussive blows to the head cause chronic traumatic encephalopathy. The neuropathological appearance of chronic traumatic encephalopathy is distinguished from other tauopathies, such as Alzheimer’s disease. The four clinical stages of observable chronic traumatic encephalopathy disability have been correlated with tau focal perivascular epicenters of neurofibrillary tangles in the frontal neocortex to severe tauopathy affecting widespread brain regions.
Diagnosis of chronic traumatic encephalopathy cannot be made in living individuals; a clear diagnosis is only possible during an autopsy. Although there are signs and symptoms some researchers associate with chronic traumatic encephalopathy there is no definitive test to prove the existence in a living person. Signs are also very similar to those of other neurological conditions, such as Alzheimer’s. several organizations, including the National Institute of Neurological Disorders and Stroke and Brain Injury Research Institute, are investing in research initiatives to learn more about chronic traumatic encephalopathy.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/chronic-traumatic-encephalopathy-market/
Global Chronic Traumatic Encephalopathy Market – Competitive Landscape
On August 11, 2023, CFL partnered with Vancouver company to combat brain trauma. On February 8, 2023, the Brain Health Consortium expanded transdisciplinary research with a merger of research institutes at UTSA. On December 10, 2020, Cyrano Therapeutics raised USD 12.8 million to complete the phase 2 trial of CYR-064 for the restoration of chronic smell and flavor loss.
Some of the Key Players in the Global Chronic Traumatic Encephalopathy Market Include –
- Medical Marijuana Inc
- Aethlon Medical
- Amaranthus Bioscience Holdings
- NIH
- Alzheimer’s Association
- Reserved Tgen
- The Stern Lab
- Diagnose CTE
Global Chronic Traumatic Encephalopathy Market – Growth Drivers
The growing global participation in sports, including high-impact contact sports, contributes to a higher prevalence of head injuries, serving as a key driver for the growth of the chronic traumatic encephalopathy market. According to the National Health Interview Survey estimated that annually USD 1.9 million persons sustain a skull fracture or intracranial injury, with such trauma making up approximately 1% of all injuries. Increasing awareness among healthcare professionals, athletes, and the general public about the long-term consequence of repetitive head trauma is driving demand for chronic traumatic encephalopathy diagnostics and research, fostering the chronic traumatic encephalopathy market growth. Continuous advancements in neuroimaging technologies, such as MRI, and PET scan, provide improved capabilities for detecting early signs of chronic traumatic encephalopathy, promoting accurate diagnosis and influencing market expansion. Growing investments in research and development by pharmaceutical and biotechnology companies to better understand chronic traumatic encephalopathy, identify biomarkers, and develop effective treatments are significant drivers propelling the market growth of chronic traumatic encephalopathy. The increasing aging population worldwide is associated with a higher incidence of neurodegenerative conditions for diagnostic tools and therapeutic interventions. Improving healthcare infrastructure, particularly in developing regions, enhances access to diagnostic facilities and healthcare services, driving the demand for chronic traumatic encephalopathy-related diagnostics and treatments.
Global Chronic Traumatic Encephalopathy Market – Restraints
Limited awareness and underreporting of head injuries, coupled with the challenge of accurately diagnosing chronic traumatic encephalopathy during a person’s lifetime, hinder the market’s growth of chronic traumatic encephalopathy. The absence of universally accepted and standardized diagnostic criteria for chronic traumatic encephalopathy poses a restraint, leading to variability in diagnoses and complicating efforts to establish a consistent approach to treatment. Currently, surrounding mental health conditions including chronic traumatic encephalopathy and misconceptions about the causes and symptoms may discourage individuals from seeking diagnosis and treatment, impeding the chronic traumatic encephalopathy market growth. Ethical considerations related to studying chronic traumatic encephalopathy, especially involving post-mortem brain tissue analysis, can pose challenges and constraints on research initiatives, affecting the pace of advancements in the field. The complex nature of neurodegenerative research, coupled with the need for extensive clinical trials and imaging studies, leads to high research and development costs, limiting investment in chronic traumatic encephalopathy-related projects. According to the National Center for Biotechnology Information (NCBI), the estimated costs per case were between USD 33,284 to USD 35,954 for mild and USD 25,174 to USD 81,153 for moderate TBI. Unequal access to advanced neuroimaging technologies, especially in developing regions, limits the widespread and timely diagnosis of chronic traumatic encephalopathy, acting as a barrier to market growth of chronic traumatic encephalopathy.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/chronic-traumatic-encephalopathy-market/
Global Chronic Traumatic Encephalopathy Market – Opportunities
The ongoing research and development in diagnostic technologies present an opportunity for more accurate and early detection of chronic traumatic encephalopathy improving patient outcomes. Identifying reliable biomarkers associated with chronic traumatic encephalopathy offers opportunities for developing diagnostics tests, enabling quicker and more precise identification of the condition. Research into novel therapeutic interventions and medications for chronic traumatic encephalopathy presents a significant opportunity to improve treatment outcomes and enhance the quality of life for individuals affected by the condition. Increased awareness and public health initiatives focused on sports safety and head injury prevention create opportunities for early intervention and induced incidence of chronic traumatic encephalopathy. The adoption of telemedicine and remote monitoring presents an opportunity to enhance accessibility to chronic traumatic encephalopathy diagnosis and management, particularly in regions with limited healthcare infrastructure.
Global Chronic Traumatic Encephalopathy Market – Geographical Insight
The market for global chronic traumatic encephalopathy is segmented into regions such as North America, Latin America, Asia-Pacific, Europe, the Middle East & Africa. North America is the largest market for global chronic traumatic encephalopathy due to attributed increased awareness, advanced healthcare infrastructure, and a higher prevalence of sport-related head injuries. Europe is the growing market for chronic traumatic encephalopathy due to rising concern about chronic traumatic encephalopathy, with an increasing number of reported cases and a growing focus on sports safety measures. Asia-Pacific is emerging as a potential market for chronic traumatic encephalopathy awareness and diagnostics, driven by a surge in sports participation and a gradual increase in recognizing and diagnosing chronic traumatic encephalopathy cases.
Global Chronic Traumatic Encephalopathy Market – Key Development
- On March 9, 2022, Minnetronix helped Oculogica launch its new EyeBox concussion diagnostic device.
- On January 5, 2022, Riddell launched Axiom, the latest helmet to combat concussions.